This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E74.1 (disorders of fructose metabolism) | Special Copayment Reduction: V286 (severe intractable disease, 5 years) |
| B. Synonyms | Hereditary fructose intolerance (HFI), fructose-1,6-bisphosphatase deficiency, essential fructosuria, hereditary fructosemia |
| C. Adult onset | Likelihood of adult onset: moderate — HFI presents at first fructose exposure in infancy, but diagnosis may be delayed into adulthood because of fructose avoidance. FBPase deficiency presents as a metabolic crisis in the neonatal to infant period. Acute crises can recur in adulthood as well when fructose is ingested. |
| 1. History | 1956: Chambers and Pratt first reported HFI → 1971: FBPase deficiency described → ALDOB gene cloned (1988) → expansion of newborn screening (2000s). |
| 2. Causes | HFI: biallelic mutations in the ALDOB gene (aldolase B); FBPase deficiency: FBP1 gene variants; essential fructosuria: KHKA/KHK-A variants (benign). |
| 3. Genetics | ALDOB (9q22.32) autosomal recessive; common variants p.A150P (Europe), p.A175D, p.N335K; FBP1 (9q22.32) autosomal recessive. |
| 4. General epidemiology | HFI prevalence about 1:18,000–1:31,000; carrier frequency in Europe about 1:65; FBPase deficiency estimated at 1:900,000 (rare). |
| 5. Pathophysiology | Aldolase B deficiency → accumulation of fructose-1-phosphate (F-1-P) → depletion of inorganic phosphate → impaired ATP resynthesis → hypoglycemia and hepatotoxicity; FBPase deficiency → blockade of gluconeogenesis → fasting hypoglycemia. |
| 6. Symptoms | After fructose intake: nausea and vomiting, abdominal pain, hypoglycemia (sweating, seizures, loss of consciousness), jaundice; with repeated exposure: hepatomegaly, cirrhosis, renal tubular dysfunction (Fanconi syndrome). |
| 7. Signs | Hepatomegaly, jaundice, hypoglycemia (lowered blood glucose, altered consciousness), elevated AST/ALT, metabolic acidosis, hyperuricemia, hypophosphatemia. |
| 8. Screening | Newborn screening (in some countries); ALDOB gene panel testing in patients suspected of fructose intolerance; urine reducing sugar test (nonspecific). |
| 9. Diagnosis | ALDOB and FBP1 gene variant analysis (diagnostic standard); measurement of aldolase B enzyme activity in red blood cells or liver tissue; fructose challenge test (not recommended because of high risk). |
| 10. Treatment | Lifelong dietary restriction of fructose, sucrose, and sorbitol; intravenous glucose during acute hypoglycemic attacks; liver and renal tubular damage are reversible (with dietary adherence). |
| 11. Prognosis | Excellent prognosis with strict dietary restriction; risk of cirrhosis and renal failure with repeated exposure; low incidence of dental caries (low sugar intake owing to fructose avoidance). |
| 12. Prevention | Avoid foods and drugs containing fructose, sucrose, and sorbitol; early diagnosis of siblings by family genetic testing; mark patient records to prohibit fructose-containing fluids and drugs when visiting medical institutions. |
| 13. References | Steinmann B et al. J Inherit Metab Dis 2005 and 9 other papers |
The history of disorders of fructose metabolism begins with the description of hereditary fructose intolerance (HFI). In 1956, Chambers and Pratt in Switzerland first described, as an independent syndrome, pediatric patients showing recurrent hypoglycemia, vomiting, and jaundice after ingesting fructose or sucrose. Subsequently, in 1957, Froesch et al. observed that serum phosphate levels fall markedly during intravenous fructose loading in this disease, and first proposed an association with abnormal phosphate metabolism.
In the 1960s the enzyme defect was identified. In 1962, Hers and Joassin confirmed that aldolase B (fructose-1,6-bisphosphate aldolase B) activity is markedly reduced in the liver tissue of HFI patients and showed that this enzyme is essential for the breakdown of fructose-1-phosphate (F-1-P). The mechanism by which F-1-P accumulation causes phosphate depletion, impaired ATP resynthesis, and hypoglycemia gradually became clear. In 1963, Schapira et al. proposed a method of establishing the diagnosis in HFI patients by a fructose challenge test, but as it became known that this test can induce severe hypoglycemia, it later became a non-recommended test.
In 1971, Baker and Winegrad described fructose-1,6-bisphosphatase (FBPase) deficiency as an independent disease. In this enzyme deficiency, gluconeogenesis is blocked, causing fasting hypoglycemia and lactic acidosis; it resembles HFI but is characterized by metabolic crises occurring with fasting alone, regardless of fructose intake.
In 1988, Brooks and Tolan cloned the ALDOB gene and identified the first gene variant associated with HFI. This opened the era of genetic diagnosis, allowing molecular genetic testing to replace diagnosis that had previously relied on enzyme activity measurement or fructose challenge testing. Dozens of ALDOB variants have since been identified, and p.A150P (formerly A149P) is known to be the most common variant, especially in European populations.
Since the 2000s, an increasing number of countries have included disorders of fructose metabolism in newborn screening, and the spread of gene panel testing is bringing the time of diagnosis forward. In addition, the paradoxical observation that dental caries decrease in HFI because of dietary restriction has been reported and used as evidence that fructose and sucrose play an essential role in caries formation.
There are three major disorders of fructose metabolism included in ICD-10 E74.1.
Biallelic loss-of-function mutations in the aldolase B (ALDOB) gene abolish aldolase B enzyme activity in the liver, kidney, and small intestine. Aldolase B is the enzyme that breaks down fructose-1-phosphate (F-1-P) and fructose-1,6-bisphosphate. Because of ALDOB gene variants, F-1-P accumulates in hepatocytes and is toxic, while inorganic phosphate (Pi) is depleted and ATP resynthesis is inhibited. It is inherited in an autosomal recessive manner, and when both parents are carriers, the disease is expressed in 25% of their children.
Biallelic loss-of-function variants in the FBP1 gene (11q23.3) abolish fructose-1,6-bisphosphatase activity. This enzyme is a key regulatory enzyme of gluconeogenesis, and when it is deficient, gluconeogenesis is blocked, causing hypoglycemia and lactic acidosis in the fasting state. The most important difference from HFI is that metabolic crises occur not only with fructose intake but also in catabolic states such as fasting, fever, and infection.
Variants in the KHK (ketohexokinase, fructokinase) gene inhibit fructose phosphorylation, so fructose is excreted in the urine. It is clinically benign, with no hypoglycemia or organ damage. It is found incidentally on a urine reducing sugar test. It is autosomal recessive, and the prevalence is about 1:130,000.
The ALDOB gene is located on chromosome 9 (9q22.32) and encodes aldolase B, composed of 364 amino acids. About 50 or more pathogenic variants have been reported to date, and the major variants differ by region. The most common variant in European patients is p.A150P (c.448G>C), accounting for about 67% of HFI alleles in Europe and presumed to have originated about 900 years ago in Western Europe through a single founder effect. The second most common variant is p.A175D (c.524C>A). In Asian patients, p.N335K is relatively more common. It is expressed as compound heterozygous or homozygous variants. The pathogenicity of ALDOB variants is explained by decreased stability of the enzyme's tetramer structure and reduced substrate-binding capacity. The FBP1 gene is located on chromosome 9 (9q22.32-q22.33) and encodes fructose-1,6-bisphosphatase. More than 50 variants have been reported, and most are inherited in an autosomal recessive manner. Genetic counseling and sibling testing are essential for early diagnosis and prevention of metabolic crises.
The prevalence of hereditary fructose intolerance (HFI) is reported in European studies at about 1:18,000–1:31,000. The carrier frequency of the ALDOB p.A150P variant in the European population is about 1:65. In New England newborn screening data, the prevalence of HFI is estimated at about 1:26,000–1:31,000. In Korea, accurate prevalence data are lacking, but it is classified as a rare disease and is eligible for Special Copayment Reduction. HFI occurs in all ethnic groups, but epidemiological data in Asian patients are limited. FBPase deficiency is much rarer than HFI, estimated at about 1/900,000, with more than 150 case reports worldwide. There is no sex difference, and it occurs in all ethnic groups. Essential fructosuria is asymptomatic, so it is rarely diagnosed and its prevalence is low.
The key to the pathophysiology of HFI is the toxic accumulation of fructose-1-phosphate (F-1-P). Normally, fructose is phosphorylated to F-1-P by hepatic fructokinase (ketohexokinase) and broken down by aldolase B into DHAP (dihydroxyacetone phosphate) and D-glyceraldehyde. In aldolase B deficiency, F-1-P accumulates in hepatocytes and is toxic by the following mechanisms. ① Depletion of inorganic phosphate: inorganic phosphate is consumed in forming F-1-P, depleting intracellular Pi. ② Impaired ATP resynthesis: Pi depletion inhibits ATP production by oxidative phosphorylation and glycolysis. ③ Excess AMP deamination: AMP increases as ATP decreases, and AMP deamination is accelerated, producing uric acid (hyperuricemia). ④ Hypoglycemia: results from the combination of ATP depletion inhibiting glycolysis, blockade of glycogenolysis (lack of phosphorylase substrate), and inhibition of gluconeogenesis. ⑤ Direct hepatotoxicity: F-1-P itself induces hepatocyte death. Prolonged F-1-P exposure progresses to hepatocyte injury, hepatic fibrosis, and cirrhosis, and also causes toxicity to the renal proximal tubule (Fanconi syndrome). In FBPase deficiency, gluconeogenesis is blocked in the fasting state, causing hypoglycemia, lactic acidosis, and ketoacidosis. Glucose synthesis from sugars, glycerol, and amino acids is all inhibited.
In HFI, clinical symptoms appear after ingestion of foods containing fructose or sucrose (sucrose = glucose + fructose). Breastfed infants have no symptoms and are first exposed when weaning foods are started. Acute symptoms: 20–30 minutes after fructose ingestion, nausea, vomiting, and abdominal pain occur, followed by hypoglycemic symptoms such as sweating, pallor, cyanosis, lethargy, seizures, and loss of consciousness. Chronic symptoms (with repeated exposure): hepatomegaly, jaundice, failure to thrive, decreased appetite, repeated vomiting, and abdominal pain persist. With progression to cirrhosis, ascites, jaundice, and coagulopathy may occur. Renal proximal tubular dysfunction (Fanconi syndrome): excessive urinary excretion of glucose, amino acids, phosphate, bicarbonate, and potassium, accompanied by rickets, growth impairment, and acidosis. Characteristically, HFI patients instinctively avoid sweet tastes and tend to voluntarily avoid foods containing fructose and sucrose. As a result, the incidence of dental caries is markedly low. In FBPase deficiency, hypoglycemia, lactic acidosis, ketoacidosis, and loss of consciousness occur with fasting or with fever or infection, sometimes accompanied by hepatomegaly.
On physical examination, hepatomegaly is the most common finding. Jaundice may accompany, and with repeated exposure, signs of cirrhosis (ascites, spider angioma, splenomegaly) appear. Failure to thrive is observed, and muscle weakness and hypotonia may accompany. Laboratory findings: acute phase — lowered blood glucose (hypoglycemia), lowered serum phosphate (hypophosphatemia), elevated uric acid (hyperuricemia), elevated bilirubin, AST, and ALT, abnormal coagulation tests (prolonged PT), and metabolic acidosis. On urinalysis, a positive reducing sugar (fructosuria), aminoaciduria, and phosphaturia suggest Fanconi syndrome. With long-term damage, findings of hepatic failure such as decreased albumin, prolonged PT, and thrombocytopenia appear. FBPase deficiency: hypoglycemia, hyperlactatemia (lactate >5 mmol/L), ketoacidosis, hepatomegaly. A poor glycemic response is confirmed on glucose loading or alanine/glycerol loading tests.
It is included in newborn screening in some countries, but is not currently among the diseases covered by newborn screening in Korea. When there is a family history (a carrier parent is identified or a sibling is confirmed), early diagnosis by genetic testing is possible. In clinical practice, it is considered in the differential diagnosis in children showing recurrent hypoglycemia, hepatomegaly, and aversion to fructose and sucrose. A urine reducing sugar test can be used as a screening tool but is nonspecific. The pattern of changes in serum phosphate, blood glucose, and uric acid after fructose exposure helps screening. Blood acylcarnitine and amino acid profiles (tandem mass spectrometry) show no HFI-specific abnormalities, so direct screening is difficult. A gene panel (including ALDOB and FBP1) is the standard for confirmation.
ALDOB gene variant analysis is the standard for diagnosing HFI. A panel of variants common in Korea or full gene sequencing is performed. When the diagnosis is unclear on genetic analysis, aldolase B enzyme activity is measured in liver tissue or red blood cells. Enzyme activity below 10% of normal is diagnostic. The intravenous fructose challenge test risks causing severe hypoglycemia and hypophosphatemia and is therefore not currently recommended in clinical practice. Blood citrate, lactate, uric acid, phosphate, and liver function tests are performed as basic tests, and abnormal findings are confirmed on urine organic acid analysis. Liver biopsy is performed only when needed to measure tissue aldolase B, to assess steatosis, hepatocellular injury, and the degree of fibrosis. Diagnosis of FBPase deficiency: FBP1 gene analysis, measurement of FBPase enzyme activity in leukocytes or liver tissue, and evaluation of metabolic response in the fasting state or on azetonic acid loading.
Dietary treatment is the only fundamental treatment. Foods and drugs containing fructose, sucrose, and sorbitol (converted to fructose in the body) are strictly excluded for life. Fructose-containing foods: most fruits, fruit juices, honey, and sweets, beverages, cakes, and jams containing sucrose. Sorbitol-containing foods: some diabetic diet products, chewing gum. Drugs also often contain fructose or sorbitol as excipients, so the ingredients must be checked whenever any drug is prescribed (especially liquid preparations). With strict adherence to dietary restriction, liver and kidney function recover and growth normalizes. Acute hypoglycemic attacks: prompt intravenous glucose (0.2 g/kg or D10W–D50W). If oral intake is possible, give a glucose solution (a preparation without fructose). FBPase deficiency: frequent glucose supplementation (raw cornstarch, etc.), avoiding prolonged fasting, and early glucose supply in catabolic states (infection, fever) are key. In a severe metabolic crisis, intravenous glucose and sodium bicarbonate (to correct acidosis) are given.
The prognosis of HFI patients who adhere to strict dietary restriction is excellent. Even if liver damage occurred before diagnosis, liver function mostly recovers after fructose avoidance. Renal tubular function also normalizes after dietary treatment. Catch-up growth is possible after dietary restriction. Progression to cirrhosis and hepatic failure can occur with long-term repeated exposure to fructose, but today this outcome can be prevented by early diagnosis and strict dietary management. The incidence of dental caries is very low. Acute symptoms can recur in adulthood if fructose is eaten by mistake, so the habit of checking food ingredients must be maintained for life. The prognosis of FBPase deficiency is also good under strict metabolic management, but neurological damage may remain if metabolic crises recur.
For HFI patients, lifelong avoidance of fructose, sucrose, and sorbitol is the only prevention strategy. After the diagnosis is confirmed, consult a dietitian and become familiar with the lists of safe foods and foods to avoid. Check all food labels carefully, and when eating out, inform kitchen staff of the need to avoid fructose. Precautions in medical institutions: inform medical staff that the patient has HFI, and prohibit the use of intravenous fluids (e.g., some nutritional fluids) and drugs containing fructose, sorbitol, or sucrose. Before surgery or procedures, inform the anesthesiologist and pharmacist so that drugs without excipients are selected. Family testing: early detection by genetic testing in siblings and children of confirmed HFI patients is important. Prenatal genetic diagnosis can be considered when carrier couples plan a pregnancy.